Raphael Schiffmann1, Markus Ries2. 1. Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas. Electronic address: Raphael.Schiffmann@BSWHealth.org. 2. Department of Pediatric Neurology and Metabolic Medicine, Center for Rare Disorders, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
BACKGROUND: Fabry disease, an X-linked disorder of glycosphingolipids, markedly increases the risk of systemic vasculopathy, ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction, and chronic kidney disease. METHODS: We performed an extensive PubMed search on the topic of Fabry disease and drew from our cumulative 43 years of experience. RESULTS: Most of these complications are nonspecific in nature and clinically indistinguishable from similar abnormalities that occur in the context of more common disorders in the general population. This disease is caused by variants of the GLA gene, and its incidence may have been underestimated. However, one must also guard against overdiagnosis of Fabry disease and unjustified enzyme replacement therapy, because some of the gene variants are benign. Specific therapy for Fabry disease has been developed in the last few years, but its clinical effect has been modest. Novel therapeutic agents are being developed. Standard "nonspecific" medical and surgical therapy is necessary and effective in slowing deterioration or compensating for organ failure in patients with Fabry disease. CONCLUSIONS: Fabry disease is a treatable and modifiable genetic risk factor for a myriad of clinical organ complications. Fabry disease may be frequently overlooked but on occasion overdiagnosed.
BACKGROUND:Fabry disease, an X-linked disorder of glycosphingolipids, markedly increases the risk of systemic vasculopathy, ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction, and chronic kidney disease. METHODS: We performed an extensive PubMed search on the topic of Fabry disease and drew from our cumulative 43 years of experience. RESULTS: Most of these complications are nonspecific in nature and clinically indistinguishable from similar abnormalities that occur in the context of more common disorders in the general population. This disease is caused by variants of the GLA gene, and its incidence may have been underestimated. However, one must also guard against overdiagnosis of Fabry disease and unjustified enzyme replacement therapy, because some of the gene variants are benign. Specific therapy for Fabry disease has been developed in the last few years, but its clinical effect has been modest. Novel therapeutic agents are being developed. Standard "nonspecific" medical and surgical therapy is necessary and effective in slowing deterioration or compensating for organ failure in patients with Fabry disease. CONCLUSIONS:Fabry disease is a treatable and modifiable genetic risk factor for a myriad of clinical organ complications. Fabry disease may be frequently overlooked but on occasion overdiagnosed.
Authors: Raffaele Manna; Roberto Cauda; Sandro Feriozzi; Giovanni Gambaro; Antonio Gasbarrini; Didier Lacombe; Avi Livneh; Alberto Martini; Huri Ozdogan; Antonio Pisani; Eleonora Riccio; Elena Verrecchia; Lorenzo Dagna Journal: Intern Emerg Med Date: 2017-07-19 Impact factor: 3.397
Authors: Daniel K Borger; Benjamin McMahon; Tamanna Roshan Lal; Jenny Serra-Vinardell; Elma Aflaki; Ellen Sidransky Journal: Dis Model Mech Date: 2017-06-01 Impact factor: 5.758
Authors: R W D Welford; A Mühlemann; M Garzotti; V Rickert; P M A Groenen; O Morand; N Üçeyler; M R Probst Journal: Hum Mol Genet Date: 2018-10-01 Impact factor: 6.150